This segment focuses on the development, commercialization, and distribution of therapies for Lambert-Eaton Myasthenic Syndrome (LEMS), a rare autoimmune disorder affecting neuromuscular function. The primary product in this segment is Firdapse, an amifampridine phosphate tablet, which is approved for the treatment of LEMS. Ruzurgi is also available for pediatric LEMS patients. Research and development activities include ongoing clinical trials and studies to expand the understanding of LEMS and improve treatment options. The segment leverages established pharmaceutical manufacturing and distribution networks to ensure patient access to these critical medications. The patient impact is significant, as these therapies directly address the debilitating muscle weakness associated with LEMS, improving quality of life. Market positioning is strong due to the limited treatment options available for LEMS. Future opportunities include exploring new formulations and indications for Firdapse and Ruzurgi, as well as potential partnerships to expand market reach. Regulatory aspects involve adherence to FDA guidelines and ongoing post-market surveillance.

This segment encompasses the research and development efforts focused on expanding the therapeutic applications of existing drugs and developing new treatments for various neuromuscular and neurological diseases. This includes ongoing clinical trials for Firdapse in conditions such as MuSK antibody positive myasthenia gravis and spinal muscular atrophy type 3, as well as hereditary neuropathy with liability to pressure palsies. The company utilizes advanced research methodologies, including clinical studies and collaborations with research institutions, to identify and validate new therapeutic targets and drug candidates. The segment aims to address unmet medical needs in rare and chronic neurological conditions, improving patient outcomes and quality of life. Market positioning is enhanced by the company's focus on rare diseases, which often have limited treatment options. Future opportunities include expanding the pipeline with new drug candidates and exploring strategic partnerships to accelerate development and commercialization. Regulatory aspects involve navigating the FDA approval process and ensuring compliance with all relevant regulations.